Green Thumb Industries (GTBIF) Consolidated Net Income (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Consolidated Net Income came in at $15.0 million in Q1 2026, up 79.11% YoY from $8.4 million in Q1 2025, and down 93.04% on a QoQ basis from $216.3 million in Q4 2025.
Green Thumb Industries (GTBIF) Consolidated Net Income (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Consolidated Net Income data on file, last reported at $15.0 million in Q1 2026.
- Quarterly Consolidated Net Income rose 79.11% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.8 million (up 63.51% YoY) and the FY2025 annual result came in at $249.2 million, up 38.89% from the prior year.
- Consolidated Net Income retreated to $15.0 million in Q1 2026, from $216.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $216.3 million in Q4 2025 to a low of -$99.0 million in Q4 2022.
- A 5-year average of $31.3 million and a median of $15.0 million in 2026 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 166.62% — and 2024, when it surged 233.31%.
- Tracing GTBIF's Consolidated Net Income over 5 years: stood at -$99.0 million in 2022, then jumped by 190.29% to $89.4 million in 2023, then surged by 32.44% to $118.4 million in 2024, then surged by 82.7% to $216.3 million in 2025, then plunged by 93.04% to $15.0 million in 2026.
- The last three Consolidated Net Income figures came in at $15.0 million (Q1 2026), $216.3 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Green Thumb Industries | 1.66 Bn | 1.37 Bn | 137.87 Mn | 3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.43 Mn |
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 216.27 Mn |
| Sep 30, 2025 | 23.80 Mn |
| Jun 30, 2025 | 732,000.00 |
| Mar 31, 2025 | 8.40 Mn |
| Dec 31, 2024 | 118.37 Mn |
| Sep 30, 2024 | 8.78 Mn |
| Jun 30, 2024 | 20.92 Mn |
| Mar 31, 2024 | 31.35 Mn |
| Dec 31, 2023 | 89.38 Mn |
| Sep 30, 2023 | 10.81 Mn |
| Jun 30, 2023 | 13.69 Mn |
| Mar 31, 2023 | 9.41 Mn |
| Dec 31, 2022 | -98.99 Mn |
| Sep 30, 2022 | 10.15 Mn |
| Jun 30, 2022 | 24.73 Mn |
| Mar 31, 2022 | 29.69 Mn |
| Dec 31, 2021 | 148.61 Mn |
| Sep 30, 2021 | 21.59 Mn |